Mucoadhesive micelles for delivery of drugs to the lung for the prophylactic treatment of COVID-19

新冠肺炎造成的死亡人数飙升，以及当前经济形势的不可持续，构成了全球迫切需要一种创新的解决方案，以在预期的经济重启后保护公众。该项目将侧重于开发一种用于新冠肺炎暴露后预防的鼻喷剂配方，这将有助于控制感染数量，进而加速公众安全地恢复正常生活，并有助于在预期的第二波疫情中进行控制。这项建议提供了一种创新、直接和可扩展的预防方法，可以通过将抗病毒药物与专有和专利的粘附性胶束相结合来自我管理，以提供对感染的长期保护效果。我们将专注于含有羟氯喹(HCQ)或一种新型血管生成素-Tie2抑制剂的鼻喷雾剂的配方，这是我们合作伙伴甘宁研究公司的专利。每种药物都将被纳入Seardown实验室的专利粘附性胶束递送系统。这些制剂将起到预防作用，要么防止导致新冠肺炎的SARS-CoV-2病毒进入呼吸道，要么将其影响和严重性降至最低。然后，它们将与曼宁合作开发用于临床。

The soaring death tolls from COVID-19 and the non-sustainability of the current economic situation pose an urgent worldwide need for an innovative solution to protect the public upon the anticipated restart of the economy. This project will focus on the development of a nasal spray formulation for post-exposure prophylaxis against COVID-19 which will help control the number of infections and, in turn, hasten the safe return of the public to normal life as well as being useful for control in the anticipated second wave. This proposal offers an innovative, straightforward and scalable prophylactic approach that can be self-administered by combining anti-viral drugs with proprietary and patented mucoadhesive micelles to provide a prolonged protective effect against infection. We will focus on the formulation of a nasal spray containing either hydroxychloroquine (HCQ) or a novel Angiopoietin-Tie2 inhibitor, which is proprietary to our partner Mannin Research Inc. Each drug will be incorporated into the patented mucoadhesive micelle delivery system from the Sheardown lab. These formulations will act as a prophylactic, either preventing entry of SARS-CoV-2, the virus responsible for COVID-19, into the respiratory tract or minimizing its impact and severity. They will then be developed for clinical use in partnership with Mannin.